Abstract
Symbioflor2® is a probiotic product composed of six Escherichia coli genotypes, which has a beneficial effect on irritable bowel syndrome. Our objective was to understand the individual impact of each of the six genotypes on the host, together with the combined impact of the six in the compound Symbioflor2®. Gnotobiotic mice were mono-associated with one of the six genotypes or associated with the compound product. Ileal and colonic gene expression profiling was carried out, and data were compared between the different groups of gnotobiotic mice, along with that obtained from conventional (CV) mice and mice colonized with the probiotic E. coli Nissle 1917. We show that Symbioflor2® genotypes induce intestinal transcriptional responses involved in defense and immune mechanisms. Using mice associated with Symbioflor2®, we reveal that the product elicits a balanced response from the host without any predominance of a single genotype. The Nissle strain and the six bacterial genotypes have different effects on the intestinal gene expression, suggesting that the impacts of these probiotics are not redundant. Our data show the effect of the Symbioflor2® genotypes at the molecular level in the digestive tract, which further highlights their beneficial action on several aspects of intestinal physiology.
Highlights
Probiotics are commonly defined as live non-pathogenic microorganisms that confer health benefits on the host, when administered in adequate amounts [1]
Our findings show that Symbioflor2® genotypes can induce the expression of genes that play a key role in intestinal homeostasis including that of enzymes involved in the turnover of reactive oxygen species, antimicrobial peptides, the intestinal barrier, solute transport, and immune responses (Tables S4 and S5, Supplementary Materials)
We found that, individually, each of the six bacterial genotypes of Symbioflor2® modifies genes involved in several cell functions, including those associated with mucosal defense
Summary
Probiotics are commonly defined as live non-pathogenic microorganisms that confer health benefits on the host, when administered in adequate amounts [1]. The most frequently used probiotics are lactic bacteria, mainly the Lactobacillus and Bifidobacterium genera, some Escherichia coli strains were shown to have beneficial effects on human health. These strains constitute the basis of at least three commercially available probiotic products, known under the commercial names Mutaflor®, Symbioflor2®, and Colinfant® [2,3]. A number of previous studies revealed the benefit of this strain in humans as an oral treatment for intestinal disorders including ulcerative colitis (UC) [4] and irritable bowel syndrome (IBS) [5,6]. E. coli Nissle was shown to be as effective as 5-aminosalicylic acid in three large studies [7,8,9], and its efficacy in maintaining remission in UC is recognized by the ECCO (European Crohn’s and Colitis Organisation) guidelines [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
